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Abstract: Background
UK hospitals nationally report venous thromboembolism (VTE) within 90-days of
hospital admission, with Hospital Acquired Thrombosis (HAT) registers at each centre
used for this. We assessed the accuracy of our HAT register in identifying VTE
following primary THR and TKR.
 
Methods
We assessed 982 elective admissions for primary THR and TKR at a large tertiary
centre during 2018. The primary outcome was any VTE (DVT and/or PE) within 90-
days post-surgery. VTEs were identified by systematically searching hospital
databases (including discharge and outpatient letters, readmissions, emergency
department visits, and imaging) for every patient. VTEs were also collected using the
HAT database at our centre, which is maintained regularly by a specialist nursing team
and used to report VTEs nationally. Diagnostic test characteristics were assessed for




The prevalence of VTE was 2.7% (n=27), with 20 VTEs identified by HAT. The
accuracy of HAT in identifying VTEs were: sensitivity=74.1% (95% CI=53.7-88.9%),
specificity=100% (CI=99.6-100%), positive predictive value=100% (CI=83.2-100%),
negative predictive value=99.3% (CI=98.5-99.7%).
 
Conclusions
One-quarter of VTEs occurring after THR and TKR were not identified by the HAT
register. These cases would be missing when our hospitals data is sent for national
VTE reporting, and therefore would have substantial implications if HAT were primarily
used to identify VTEs in a trial. Further work is needed to improve the accuracy of HAT
VTE reporting before this could be relied upon in this setting.
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Dr John J. Callaghan  
Editor in Chief 
Journal of Arthroplasty 
 
13th March 2020 
Dear Dr Callaghan,  
Re: “Can we use routinely collected healthcare data for a nationwide trial on venous 
thromboembolism prophylaxis following primary joint replacement? A feasibility study”  
(JOA-D-19-02075) 
We are very grateful for the opportunity to revise the above manuscript and we thank the Editor and 
the Reviewers for their constructive comments, which we believe have helped improve the 
manuscript. 
We have responded to the specific comments below and made revisions accordingly in the 
manuscript. We have provided one clean copy of the manuscript as requested. Details are provided 
below.  
We have submitted and formatted our paper as a “Brief Communication” article for the journal. The 
instructions on the journal website for this type of piece are as follows: 
Brief Communications are meant to be reports that promptly disseminate new ideas and 
observations. These ideas may not be sufficiently mature or evaluated to merit publication as a full 
manuscript and yet may be of interest and importance. An example would be the report of a group of 
catastrophic failures of a new implant design that would serve as an early warning to the readership. 
Brief Communications will be limited to 2 printed pages, including text, tables, figures, and 
references. This corresponds to 6 double-spaced standard manuscript pages, with 1 page of text 
eliminated for every figure or table added. References should be limited to less than 10. In addition, 
the standard complete format for papers—introduction, materials and methods, results, and 
discussion—may be eliminated; however, please include a brief abstract. Brief Communications will 
be reviewed as soon as possible and, when accepted, published in the next possible issue. 
 
We believe the topic and content of our paper is well suited for a Brief Communication article. 
However we consider that a number of the comments made by Reviewer 2 (below) are beyond the 
scope of this article type given the tight constraints on word count and formatting for a Brief 
Communication article, so we have regrettably been unable to action all of these changes 
comprehensively in the revised manuscript. However we have done our best to answer the 
questions raised in the response letter, and where space permitted included these in the revised 
manuscript. We hope that these responses will be suitable given the paper has been submitted as a 
Brief Communication article.  
Response to reviewer comments 
Reviewer Number 1:  
1. This brief communication reported the accuracy of the HAT register in identifying VTE following 
primary THA and TKA. The results showed one-quarter of VTES were not identified by the HAT 





register. I think this manuscript is good and reflects the real situation when we use the data 
from some big databases. This manuscript is good English writing and easy to read.  
We thank reviewer 1 for their kind comment.  
 
2. The only thing I want to mention is, according to the study, 7 VTEs were missed by HAT. Could 
the authors analyze the reasons for the 7 cases of missing? If possible, a table for each case is 
better. I think this might help the readers know more about the real situation if they want to 
get data from the HAT register. 
Many thanks for this suggestion. As this is a Brief Communication article we have elected to add 
some text about why the 7 cases where missed (page 5, lines 95-98), rather than a table which 
removes a page of space in the manuscript as per the journal instructions. We have also discussed 
the missing cases when considering mechanisms for quality improvement of the HAT register at our 
hospital (page 7, lines 139-140). 
 




3. This is a very interesting paper. It shows one of the important weaknesses of registries and 
other large administrative databases which is data entry. All of these registries require quality 
of data assessment to ensure that all the data is entered accurately and not missed. This means 
that the papers that might have used HAT register only, might not represent the accurate data. 
I recommend revision to provide more details as well as clarifications. 
We thank reviewer 2 for their kind comment.  
 
4. Please provide your hypotheses at the end of the introduction section 
We have now added our hypothesis at the end of the introduction section (page 3, lines 61-62). 
 
5. Please provide the reason you chose to review 982 patients? How did you calculate your sample 
size? 
This was a sample size of convenience as it included all primary hip and knee arthroplasty patients 
over a one-year calendar period (2018) treated at our centre. The authors considered this sample 
size provides the paper with sufficient numbers to undertake the proposed work, as we needed to 
ensure there were going to be sufficient numbers of outcome events (i.e. VTEs) for assessment. 
However we believe that a formal sample size calculation is beyond the scope of this feasibility work 
on the use of a routinely collected dataset for potential future outcome assessment in a trial and for 
the limits imposed by the instructions for a “Brief Communication” article (see journal instructions 
for this type of article above on page 1). 
 
6.  Please provide the study purpose and study hypotheses at the end of the introduction section. 
We consider that the first 2 paragraphs of the introduction set the background and purpose of the 




the paper in the “Brief Communication” article format and tight limits, then we would be happy to 
make subsequent alterations to this section. As per our response to reviewer comment 4, we have 
added a formal hypothesis as requested.   
 
7. Are you comparing 2 HAT databases, one local and one national? Please clarify. 
We are only assessing the accuracy of our local HAT database at our centre. How the HAT database 
functions at our centre is described (page 4, lines 78-85). This local HAT database is being compared 
to the existing “gold-standard” of systematic searches of all medical records available for all patients 
who underwent arthroplasty at our centre during the study period (details on page 4, lines 69-76). 
There is no distinct and separate national HAT database. The VTE rates at 90-days from local HAT 
databases are submitted to national authorities, with our data then combined with data from other 
local HAT databases at other hospitals to give a national VTE rate across all hospitals (note that we 
do not have access to these national VTE rates, or rates at other hospitals). We have made changes 
in the text to emphasise the process (see above pages/lines cited in this response). 
 
8. If you are comparing your hospital HAT register with local or national HAT register: has your 
hospital HAT register been quality checked? You mention your hospital database as gold standard. 
How do you know your hospital database is accurate? 
Please see our response to reviewer comment 7 which addresses most of these issues. The current 
piece of work was conducted to assess the quality of data in our hospital HAT register in comparison 
to the existing alternative mechanism for data collection which involves screening of all available 
data sources within the unit to identify detected events. We point out in the introduction that the 
accuracy of HAT registers at any hospital is unknown (page 3, line 58), therefore we feel this is an 
important piece of work given the drive to use data from registers for outcomes assessment in 
research, including trials. We do not know the accuracy of our “hospital database”, which included 
all available sources (discharge and outpatient letters, electronic records, readmissions, emergency 
department visits and imaging) for every patient. These are all the clinical records available for every 
patient consultation/event in the hospital, which we would expect to be accurate as they are used 
for routine clinical care on a daily basis. However this would be difficult to check as it is not clear 
what the “gold-standard” would be such a case, unless a formal large cohort study was performed 
which would require the use of invasive testing such as venogram to determine the absolute rate 
and hence be very expensive, time-consuming and associated with risk. We have already highlighted 
potential limitations with both HAT and our hospital database in the discussion (page 6, lines 127-
129). 
 
9. If this HAT register is national or at least multicenter, could it be possible that your data 
abstracters who enter the data to the HAT register are the reason for inaccuracy and other 
hospitals are doing better? Have you had a chance to compare your hospital data with others? 
This is a local HAT register so the issue regarding data abstracters is not relevant. We have not had 
chance to compare our hospital data with others, as the accuracy of HAT registers at any hospital is 
currently unknown. 
 
10. How did you identify the patients in the database and HAT register? CPT/ICD-9 code…? Could it 





Details of how patients with VTEs were identified are described, and have now been expanded (page 
3, lines 69-85). CPT/ICD-9 codes were not used hence we believe that this will not have introduced 
bias into our study. 
 
11.  Please clarify the routine diagnostic process for diagnosis of VTE in your hospital. Did you 
consider very small subsegmental PEs positive for VTE? 
We have clarified the investigations used for diagnosing VTE, which would extend to include 
subsegmental PEs (however none of the PEs identified were very small subsegmental) (page 3, lines 
73-75). However given this is a “Brief Communication” article we do not have the space to provide 
more details about the routine diagnostic process for VTEs at our hospital. 
 
12. If the HAT register that you investigated is multicenter or national register, has it been quality 
checked before? If yes, this has to be mentioned in the introduction and also discussion. 
As per above responses, the HAT register was local. In the introduction we have highlighted the fact 
that the accuracy of HAT registers at any hospital is currently unknown (page 3, line 58). 
 
13. You need to add a dedicated statistical analysis section. You need to have hypotheses 
mentioned in the introduction section 
A dedicated statistical analysis section is beyond the scope of the work required for a “Brief 
Communication” article (see journal instructions for this type of article above on page 1, and also 
previous “Brief Communication” articles published in the journal). However we have expanded the 
last paragraph of the Methods section (page 5, lines 87-91) to highlight exactly what was done from 
a statistical analysis aspect. We feel this is sufficient given this is essentially an analysis of diagnostic 
test characteristics using a two by two table, which can be performed relatively simply. Please see 
our response to reviewer comment 4 regarding the addition of a study hypothesis. 
 
14. What analysis methods did you use? Please provide details and rationale. 
Please see our response to reviewer comment number 13 above. Diagnostic test characteristics is 
the accepted method of assessing the accuracy of one test/method against what is considered a 
“gold-standard” test/method. 
 
15. How did you calculate your sample size? 
Please see our response to reviewer comment 5 above. We believe that a formal sample size 
calculation is beyond the scope of the work required for a “Brief Communication” article (see journal 
instructions for this type of article above on page 1). 
 
16. You have 2 independent investigators. How did you compare their results to ensure they 
match? 
We have now made it clear that between 2 investigators all records were reviewed, however there 
was no overlap (i.e. the same record being reviewed by both investigators) (page 4, lines 71-73). This 
decision was taken given the need to balance the workload (as a vast number of records/hospital 
databases needed to be reviewed for nearly 1000 patients) and in light of the outcome being 
assessed (which was a categorical diagnosis of VTE recorded in imaging reports or official/formal 
hospital documentation). We recognise this is a limitation and have highlighted this in the Methods 




outside the scope of a “Brief Communication” article given the reasons cited above to complete this 
piece of work. 
 
17. Please provide more details about the plans for HAT register data quality improvement. Some 
details about the papers published using this register is also important. These papers (if any) might 
need to be retracted etc if the quality of their data was low. 
 We have now expanded on our quality improvement plans as much as we can (which include 
highlighting specifically why the cases were missing from the HAT database), whilst keeping in mind 
this is a “Brief Communication” article (page 7, lines 138-145). We have added a reference (number 
11) to the only paper we are aware of which uses HAT data following joint replacement, and have 
highlighted caution with interpretation of this paper given our findings (page 6, lines 132-136). 
 
We hope that these responses meet with your approval and that you will now consider the 
manuscript for publication in ‘The Journal of Arthroplasty’. 
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UK hospitals nationally report venous thromboembolism (VTE) within 90-days of hospital 7 
admission, with Hospital Acquired Thrombosis (HAT) registers at each centre used for this. 8 
We assessed the accuracy of our HAT register in identifying VTE following primary THR 9 
and TKR. 10 
 11 
Methods 12 
We assessed 982 elective admissions for primary THR and TKR at a large tertiary centre 13 
during 2018. The primary outcome was any VTE (DVT and/or PE) within 90-days post-14 
surgery. VTEs were identified by systematically searching hospital databases (including 15 
discharge and outpatient letters, readmissions, emergency department visits, and imaging) for 16 
every patient. VTEs were also collected using the HAT database at our centre, which is 17 
maintained regularly by a specialist nursing team and used to report VTEs nationally. 18 
Diagnostic test characteristics were assessed for HAT in identifying VTEs compared to the 19 
gold standard (i.e. VTE’s from the hospital databases). 20 
 21 
Results 22 
The prevalence of VTE was 2.7% (n=27), with 20 VTEs identified by HAT. The accuracy of 23 
HAT in identifying VTEs were: sensitivity=74.1% (95% CI=53.7-88.9%), specificity=100% 24 
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 2 
(CI=99.6-100%), positive predictive value=100% (CI=83.2-100%), negative predictive 25 
value=99.3% (CI=98.5-99.7%). 26 
 27 
Conclusions 28 
One-quarter of VTEs occurring after THR and TKR were not identified by the HAT register. 29 
These cases would be missing when our hospitals data is sent for national VTE reporting, and 30 
therefore would have substantial implications if HAT were primarily used to identify VTEs 31 
in a trial. Further work is needed to improve the accuracy of HAT VTE reporting before this 32 
could be relied upon in this setting. 33 
 34 
Key words 35 




Over 200,000 total hip and knee replacements (THR and TKR) are performed annually in the 39 
UK.1, 2 These patients are at risk of venous thromboembolism (VTE), which is associated 40 
with mortality, significant morbidity and healthcare costs.3 Almost all patients receive 41 
chemical VTE prophylaxis for up to 6-weeks postoperatively,4,5 although the optimum 42 
thromboprophylactic agents remain unknown. NICE recommends numerous options with 43 
equal weighting, including low-molecular weight heparin (LMWH), aspirin (with or without 44 
LMWH) and newer direct oral anticoagulants (rivaroxaban, apixaban, dabigatran).4 Level 1 45 
evidence to support selection of VTE prophylaxis is lacking, so NICE have recommended 46 
large multi-centre randomised controlled trials (RCTs) are needed to assess clinical and cost-47 
effectiveness.4 RCTs are difficult given the need for large sample sizes,6 the low 90-day VTE 48 
event rate (1-2%)7 and the cost and complexity of running such large trials.  49 
 50 
Outcomes could be obtained using routinely collected healthcare datasets. This would 51 
substantially reduce costs and increase feasibility for trials comparing VTE prophylaxis. For 52 
example, the NHS has a national mandatory register for surgical site infection within 30-days 53 
of orthopaedic surgery, with this data used to drive quality improvement.8 NHS hospitals 54 
must report all VTEs within 90-days of hospital admission to their Clinical Commissioning 55 
Group (CCG) quarterly, which are subsequently submitted to Public Health England. 56 
Hospital Acquired Thrombosis (HAT) registers at each individual hospital were developed 57 
for this purpose. However the accuracy of the HAT registers at any hospital is unknown. 58 
 59 
We assessed the accuracy of our institutions HAT register in identifying VTEs following 60 
THR and TKR. Our null hypothesis was that there was no difference between the VTE events 61 
identified in the HAT register compared with the actual reported VTE events at our hospital.  62 
 4 
Methods 63 
We reviewed all elective primary THR and TKR admissions at a UK tertiary centre between 64 
1st January 2018 and 31st December 2018. 982 joint replacements were eligable, consistent 65 
with nationally submitted data.1, 9 The primary outcome was any VTE (deep vein thrombosis 66 
and/or pulmonary embolism) within 90-days following surgery, as recommended by NICE.4 67 
 68 
VTE events within 90-days of surgery were identified by systematically searching all hospital 69 
databases (discharge and outpatient letters, electronic records, readmissions, emergency 70 
department visits and imaging) for every patient. Between two authors, all records were 71 
reviewed. However authors did not review the same records so no formal inter-observer 72 
reliability assessment was performed. Authors recorded all confirmed imaging evidence of 73 
any VTEs regardless of symptoms (computerised tomography pulmonary angiography and/or 74 
venous ultrasonography), and any VTEs detailed on patient letters and electronic records. 75 
Both authors were blinded to HAT data. 76 
 77 
VTEs occurring at our centre were also collected using the hospitals local HAT database 78 
(started in 2014), with this data subsequently submitted to inform national VTE rates. 79 
Patients presenting and/or admitted with VTEs within 90-days of any hospital admission 80 
were identified by specialist nurses from two-weekly data extracts, provided by Information 81 
Analysts at the hospital, of all VTEs occurring following any admission. The HAT database 82 
is maintained regularly, and a root cause analysis is performed for all VTEs. We used any 83 
VTE recorded in HAT during the study period and within 90-days following the study end 84 
date (i.e. after 31st December 2018). 85 
 86 
 5 
VTE events recorded from HAT were cross-referenced with those collected from the hospital 87 
database searches, and a two-by-two contingency table was constructed. Diagnostic test 88 
characteristics (sensitivity, specificity, positive and negative predictive values) were then 89 
calculated (with 95% confidence intervals (CIs)) for the HAT register in identifying VTEs 90 
compared to the current standard (VTE’s from the systematic hospital database searches). 91 
 92 
Results 93 
The prevalence of VTE from the hospital database search was 2.7% (n=27). Twenty of these 94 
VTEs were identified by HAT, and HAT did not identify any additional VTEs. Of the 7 cases 95 
of VTE missed by the HAT register, 5 were identified from radiological investigations (some 96 
during inpatient stays, and some as an outpatient) and 2 were identified from outpatient 97 
letters. 98 
 99 
The diagnostic test characteristics for the HAT register in detecting VTEs identified by the 100 
gold-standard systematic hospital database searches were: sensitivity=74.1% (CI=53.7-101 
88.9%), specificity=100% (CI=99.6-100%), positive predictive value=100% (CI=83.2-102 
100%), and negative predictive value=99.3% (CI=98.5-99.7%). 103 
 104 
Discussion 105 
One-quarter of VTEs occurring after joint replacement at our hospital were not identified by 106 
the HAT register. This is concerning given our hypothesis, and that HAT data from each 107 
hospital is used to report VTE rates nationally. In its current format, the HAT database event 108 
rates could not primarily be used for RCT outcome reporting. 109 
 110 
 6 
Using routinely collected data for outcome assessment in large RCTs has many potential 111 
advantages, namely saving money, time, and resources. We have met with our own Patient 112 
and Public Involvement group, which included patients with musculoskeletal conditions, to 113 
discuss this concept.10 The group was unanimously supportive towards using routinely 114 
collected healthcare data for collecting outcomes in large trials. They felt that if this were 115 
shown to be valid compared with more traditional methods (like questionnaires or 116 
investigations), this would be preferable for many future studies rather than intensive patient 117 
follow-up and/or investigation, but only if the data was reliable. 118 
 119 
Contrary to the potential advantages of routinely collected healthcare data for patients, 120 
researchers, and clinicians, our institutions HAT database is not currently accurate enough to 121 
be used for reporting VTE outcomes in large RCTs. Although any missing VTE data would 122 
likely be missing at random from each intervention arm of any RCT, large centre sample 123 
sizes would be required to ensure this, and there is still potential for bias. Such issues must be 124 
balanced against the feasibility and cost of doing an RCT with VTEs detected using more 125 
traditional consultations and questionnaires. A large ongoing trial of 25,000 patients in the 126 
United States has cost over $14 million.6 A limitation of both the HAT register and our 127 
search of local databases, was that we would not be able to identify cases where patients had 128 
a VTE treated in another hospital or region. Furthermore, each hospital locally devised 129 
services to collect VTEs for the HAT register given that CCGs do not specify how to do this. 130 
Therefore there will be variability between the quality of HAT registers between hospitals, 131 
which will have implications for accuracy and data quality. However our findings do now 132 
question the accuracy of previous reports that have relied on HAT registers to identify VTEs 133 
following arthroplasty,11 and findings from these previous studies must be interpreted with 134 
 7 
caution until the respective centres have assessed the accuracy of their own HAT registers for 135 
VTE reporting. 136 
 137 
We have used our findings to drive quality improvement locally for our HAT register. After 138 
investigating reasons for HAT missing 7 VTEs (including 5 missed from radiological 139 
investigations) we have proposed improvements in discharge letters (i.e. documenting any 140 
inpatient investigation of VTEs regardless of if they were negative or not treated; and clearly 141 
stating when aspirin discharge prescriptions are for VTE prophylaxis rather than being 142 
assumed to be for analgesia/pre-existing conditions), and also routinely searching all imaging 143 
within 90-days of joint replacement. We plan to reassess the accuracy of our hospitals HAT 144 
database in due course to assess for quality improvement. 145 
 146 
Conclusions 147 
One-quarter of VTEs occurring after primary THR and TKR were not identified by the HAT 148 
register. These cases would be missing when our hospitals data is sent for national VTE 149 
reporting. Therefore this would have substantial implications if HAT was primarily used to 150 
identify VTE events in RCTs, and any future study relying on this should validate outcome 151 
capture as we have done here. Further work is needed to assess, and if needed improve, the 152 
accuracy of HAT registers at many hospitals for VTE reporting before this could be relied 153 
upon in multicentre studies.  154 
 8 
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